890 assets in Neoplasm

Therapeutic assets addressing Neoplasm, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Romiplostim Neoplasm	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	B (56)
Tislelizumab Neoplasm	InxMed (Shanghai) Co., Ltd.	P2	B (56)
Volitinib Neoplasm	AstraZeneca	P3	B (56)
Avelumab Neoplasm	Pfizer	P3	CCC (55)
Belrestotug Neoplasm	GlaxoSmithKline	P2	CCC (55)
Capmatinib Neoplasm	Cancer Research UK	P2/3	CCC (55)
Immunoglobulin G1, Anti-(Human Vascular Endothelial Growth Factor Receptor Type Vegfr-2 Extracellular Domain) (Human Monoclonal Imc-1121B .Gamma.-Chain), Disulphide With Human Monoclonal Imc-1121B .Kappa.-Chain, Dimer Neoplasm	Elevation Oncology	P2	CCC (55)
Melphalan Neoplasm	Jonsson Comprehensive Cancer Center	P1/2	CCC (55)
Regorafenib Neoplasm	Helsinki University Central Hospital	P2	CCC (55)
Rituximab Neoplasm	University of California, San Diego	P2	CCC (55)
Sevoflurane Neoplasm	Hong Kong Children's Hospital	P4	CCC (55)
Surufatinib Neoplasm	Hutchmed	P1/2	CCC (55)
Tamoxifen Neoplasm	DR. DIANE CHISESI NFS. MD. PHD.	P2	CCC (55)
Bendamustine Neoplasm	UNC Lineberger Comprehensive Cancer Center	P3	CCC (54)
e7389-lf Neoplasm	Eisai Co., Ltd.	P1/2	CCC (54)
Elraglusib Neoplasm	Actuate Therapeutics Inc.	P2	CCC (54)
Fluzoparib Neoplasm	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	P3	CCC (54)
Immunoglobulin G1, Anti-(Human Epidermal Growth Factor Receptor Her2) (Human-Mus Musculus Monoclonal Shr-1805 ?1-Chain), Complex With Human-Mus Musculus Monoclonal Shr-1805 ?-Chain, Dimer, Thioether With N-[6-(3-Mercapto-2,5-Dioxo-1-Pyrrolidinyl)-1-Oxohexyl]Glycylglycyl-L-Phenylalanyl-N-[[(1R)-1-Cyclopropyl-2-[[(1S,9S)-9-Ethyl-5-Fluoro-2,3,9,10,13,15-Hexahydro-9-Hydroxy-4-Methyl-10,13-Dioxo-1H,12H-Benzo[De]Pyrano[3?,4?:6,7]Indolizino[1,2-B]Quinolin-1-Yl]Amino]-2-Oxoethoxy]Methyl]Glycinamide Neoplasm	Haihua Yuan	P2	CCC (54)
Immunoglobulin G1 [De-448-Lysine], Anti-(Human Epidermal Growth Factor Receptor) (Human-Mouse Monoclonal C225 ?1-Chain) Fusion Protein With Peptide Linker (Ggggs)2 Fusion Protein With Immunoglobulin Anti-(Human Epidermal Growth Factor Receptor Her3) (Human Clone Her3.H3 Single-Chain Variable Fragment Vh-(Ggggs)3-Vl), Complex With Human-Mouse Monoclonal C225 ?-Chain, Dimer, 214??,214???,222,222?,228,228?,231,231?-Octakis(Thioether) With (2S)-N-(Carboxymethyl)-2-(3-Mercapto-2,5-Dioxo-1-Pyrrolidinyl)-?-Alanylglycylglycyl-L-Phenylalanyl-N-[[(1S)-2-[[(1S,9S)-9-Ethyl-5-Fluoro-2,3,9,10,13,15-Hexahydro-9-Hydroxy-4-Methyl-10,13-Dioxo-1H,12H-Benzo[De]Pyrano[3?,4?:6,7]Indolizino[1,2-B]Quinolin-1-Yl]Amino]-1-Methyl-2-Oxoethoxy]Methyl]Glycinamide Neoplasm	Sichuan Baili Pharmaceutical Co., Ltd.	P2	CCC (54)
Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer Neoplasm	Mohammed Milhem	P2	CCC (54)
Methotrexate Neoplasm	Yancheng First People's Hospital	P2	CCC (54)
sar444881 Neoplasm	M.D. Anderson Cancer Center	P2	CCC (54)
Vemurafenib Neoplasm	Seoul National University Bundang Hospital	P2	CCC (54)
[18F]Fluoropivalate Neoplasm	University College, London	P2	CCC (53)
Abemaciclib Neoplasm	Tango Therapeutics, Inc.	P2	CCC (53)
Adebrelimab Neoplasm	Beidahuang Industry Group General Hospital	P2	CCC (53)
Allogeneic Tumour Lysate Neoplasm	Elios Therapeutics, LLC	P2	CCC (53)
Auto Car T Cell Therapy Neoplasm	Autolus Limited	P2	CCC (53)
Bcma Car-T Cells Neoplasm	Zhejiang University	P2	CCC (53)
Busulfanum Neoplasm	University of Rochester	P2	CCC (53)
Fluorine (18F) Psma 1007 Neoplasm	AHS Cancer Control Alberta	P2	CCC (53)
Golcadomide Neoplasm	M.D. Anderson Cancer Center	P2	CCC (53)
Isatuximab Neoplasm	Hellenic Society of Hematology	P2	CCC (53)
L-Methionine Neoplasm	St. Jude Children's Research Hospital	P2	CCC (53)
Penpulimab Neoplasm	The First Affiliated Hospital with Nanjing Medical University	P2	CCC (53)
Polatuzumab Vedotin Neoplasm	The First Affiliated Hospital of Soochow University	P2	CCC (53)
Ranitidine Neoplasm	Hellenic Society of Hematology	P2	CCC (53)
Sagramostim Neoplasm	Vestre Viken Hospital Trust	P2	CCC (53)
Selinexor Neoplasm	Memorial Sloan Kettering Cancer Center	P2	CCC (53)
Selpercatinib Neoplasm	Fondazione per la Medicina Personalizzata	P2	CCC (53)
Trastuzumab Emtansine Neoplasm	Seoul National University Bundang Hospital	P2	CCC (53)
Tucidinostat Neoplasm	Tianjin Medical University Second Hospital	P2	CCC (53)
Tumor Lysate, Particle Only Vaccine Neoplasm	Elios Therapeutics, LLC	P2	CCC (53)
Tuvonralimab Neoplasm	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
uv1 Neoplasm	Vestre Viken Hospital Trust	P2	CCC (53)
Vipivotide Tetraxetan Neoplasm	Australian and New Zealand Urogenital and Prostate Cancer Trials Group	P2	CCC (53)
Zanubrutinib Neoplasm	The First Affiliated Hospital of Soochow University	P2	CCC (53)
abn401 Neoplasm	Yonsei University	P2	CCC (52)
Absk043 Neoplasm	Abbisko Therapeutics Co, Ltd	P2	CCC (52)
Afuresertib Neoplasm	Laekna Limited	P1/2	CCC (52)

Showing 101 to 150 of 890 assets

PreviousPage 3 of 18Next